Festus Uzokwe, MD
Psychiatry · Houston, TXNPI 1275532046
Payments from drug & device makers
Across 92 payments — averaging $33.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Teva Pharmaceuticals USA, Inc.$777
- Alkermes, Inc.$392
- Otsuka America Pharmaceutical, Inc.$250
- Indivior Inc.$95
- AbbVie$92
- plus $375 from 8 others
What the payments were for
- Food & beverage$2,85994%
- Education$1816%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 27 | $1,058 |
| Teva Pharmaceuticals USA, Inc. | 22 | $777 |
| Alkermes, Inc. | 10 | $392 |
| Otsuka America Pharmaceutical, Inc. | 10 | $250 |
| Indivior Inc. | 4 | $95 |
| AbbVie | 4 | $92 |
| Bioxcel Therapeutics, Inc. | 1 | $87 |
| Neurocrine Biosciences, Inc. | 3 | $82 |
| Sunovion Pharmaceuticals Inc. | 5 | $80 |
| E.r. Squibb & Sons, L.L.C. | 2 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Tris Pharma Inc | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$880
- INVEGA SUSTENNA$132
- INVEGA TRINZA$132
- UZEDY$123
- SPRAVATO$111
How this compares
$3,039 in reported general payments places this provider in the 80th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 141 | $373,227 |
| IngrezzaValbenazine Tosylate | 33 | $293,430 |
| Abilify MaintenaAripiprazole | 49 | $131,411 |
| RexultiBrexpiprazole | 60 | $107,235 |
| AristadaAripiprazole Lauroxil | 16 | $52,500 |
| Chlorpromazine Hcl | 158 | $50,272 |
| FanaptIloperidone | 25 | $50,197 |
| LybalviOlanzapine/Samidorphan Malate | 32 | $49,810 |
| PerserisRisperidone | 15 | $36,345 |
| Divalproex Sodium ErDivalproex Sodium | 617 | $35,924 |
| Aripiprazole | 322 | $34,034 |
| Risperdal ConstaRisperidone Microspheres | 21 | $29,612 |
| Paliperidone ErPaliperidone | 98 | $25,540 |
| Risperidone ErRisperidone Microspheres | 13 | $25,194 |
| VraylarCariprazine Hcl | 15 | $20,051 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta, Risperdal | $1,058 | $406,653178 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $82 | $293,43033 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $250 | $238,646109 claims |
| Alkermes, Inc.Aristada, Lybalvi | $392 | $102,31048 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $15 | $50,19725 claims |
| Indivior Inc.Perseris | $95 | $36,34515 claims |
| AbbVieVraylar | $92 | $20,05115 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $22 | $18,98433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Houston
- Matthew BramsHouston$3M
- Lawrence GinsbergHouston$2.4M
- Asim ShahHouston$2.2M
- Aqeel HashmiHouston$1.3M
- Robert EarleHouston$1.1M
- Frank ChenHouston$941K
- Joao de QuevedoHouston$890K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.